

VUNO Med®-DeepCARS® is an AI-powered medical device designed to predict the risk of in-hospital cardiac arrest within the next 24 hours for patients in general wards. By continuously analyzing vital signs—including blood pressure, heart rate, respiratory rate, and body temperature—DeepCARS® provides a risk score ranging from 0 to 100, enabling healthcare professionals to monitor patients effectively and manage risks proactively. Key Features and Functionality: - Simplicity: Utilizes only four vital signs to generate a cardiac arrest risk score, facilitating straightforward integration into existing clinical workflows. - Effectiveness: Demonstrated high predictive accuracy in multicenter studies, with an area under the receiver operating characteristic curve (AUROC) of 0.860 in internal validation and 0.905 in external validation. - Efficiency: On average, provides a 15.8-hour lead time from the first prediction to the actual occurrence of cardiac arrest, allowing for timely clinical interventions. Primary Value and User Benefits: DeepCARS® addresses the critical need for early detection of potential cardiac arrests in hospitalized patients. By offering timely and accurate risk assessments, it empowers healthcare providers to intervene proactively, thereby enhancing patient safety and improving clinical outcomes. Its simplicity and efficiency make it a valuable tool in general wards, supporting medical staff in delivering prompt and effective care.

VUNO Med®-BoneAge™ is an AI-powered diagnostic tool designed to assist healthcare professionals in assessing bone age through the analysis of hand X-ray images. By leveraging deep learning algorithms, it automatically evaluates the X-ray and presents the three most probable bone age candidates, streamlining the diagnostic process and enhancing accuracy. This solution is particularly beneficial in diagnosing growth disorders, such as short stature, tall stature, early or late puberty, and congenital adrenal hyperplasia, by providing precise bone age assessments. Key Features and Functionality: - Automated Bone Age Assessment: Utilizes AI to analyze hand X-ray images, delivering the top three most likely bone age results based on the Greulich-Pyle (GP) method, which categorizes males into 31 groups and females into 27 groups. - Efficient Workflow Integration: Reduces the time required for bone age evaluation by eliminating the need for manual comparison with reference materials. Clinicians can quickly select the most appropriate age from the provided options, enhancing workflow efficiency. - Comprehensive Reporting: Generates detailed reports that include visual graphs projecting the patient's final height, considering factors such as current age, height, and gender. This facilitates clear communication between healthcare providers and patients, improving patient engagement and satisfaction. - Regulatory Approvals: Recognized as Korea's first AI medical device, VUNO Med-BoneAge has received approvals from the Korean Ministry of Food and Drug Safety (MFDS) and the European CE certification, ensuring compliance with international medical standards. Primary Value and User Benefits: VUNO Med-BoneAge addresses the challenges associated with traditional bone age assessment methods, which can be time-consuming and subject to variability among clinicians. By automating the evaluation process, it significantly reduces reading time and enhances the consistency and accuracy of assessments. This leads to more reliable diagnoses of growth-related conditions, enabling timely and appropriate interventions. Additionally, the user-friendly interface and comprehensive reporting support effective communication with patients, fostering better understanding and adherence to treatment plans.

VUNO Med-Fundus AI is an advanced AI-powered diagnostic support solution designed to analyze retinal fundus images, aiding in the detection and diagnosis of various retinal diseases. By leveraging deep learning algorithms trained on a vast dataset of over 100,000 fundus images, this tool provides rapid and accurate identification of critical abnormalities, enhancing the efficiency and accuracy of ophthalmic assessments. Key Features and Functionality: - Detection of 12 Abnormalities: The system identifies and locates twelve essential retinal abnormalities, including drusen, hemorrhage, hard exudate, cotton wool patch, vascular abnormality, glaucomatous disc change, retinal nerve fiber layer defect, membrane, chorioretinal atrophy, non-glaucomatous disc change, macular hole, and myelinated nerve fiber. - Automated Region Mapping: It automatically detects the optic disc and macula, segmenting the fundus into eight regions—macular, superior optic disc, inferior optic disc, temporal, superotemporal, inferotemporal, superonasal, and inferonasal—to assist in precise localization of detected abnormalities. - Comprehensive Patient Reports: The software generates detailed reports that visualize detected anomalies, facilitating clear communication between healthcare providers and patients. Primary Value and User Benefits: VUNO Med-Fundus AI significantly enhances the diagnostic workflow for ophthalmologists by providing swift and accurate detection of retinal abnormalities. This leads to earlier identification of conditions such as diabetic retinopathy, macular degeneration, and glaucoma, which are critical for preventing vision loss. The system's efficiency reduces the time required for image analysis, allowing clinicians to focus more on patient care. Additionally, the clear visualization of findings improves patient understanding and engagement in their treatment plans.

VUNO Med®-Chest X-ray™ is an AI-powered diagnostic support solution designed to assist healthcare professionals in interpreting chest X-ray images. By analyzing key thoracic abnormalities, it enhances the detection and diagnosis of major lung diseases such as lung cancer, tuberculosis, and pneumonia. Key Features and Functionality: - Detection of Major Abnormalities: The system identifies five critical thoracic findings: nodule/mass, consolidation, interstitial opacity, pneumothorax, and pleural effusion. - Intuitive User Interface: Provides clear visualizations, including abnormality scores and lesion heatmaps, to aid in clinical decision-making. - Seamless Integration: Compatible with Picture Archiving and Communication Systems (PACS) and offers cloud-based services for flexible deployment. - Rapid Analysis: Delivers results in under 10 seconds, facilitating prompt clinical responses. - Regulatory Approvals: Certified by the Korea Ministry of Food and Drug Safety (MFDS) and holds CE certification, ensuring compliance with international medical device standards. Primary Value and User Benefits: VUNO Med®-Chest X-ray™ streamlines the diagnostic process by providing immediate, accurate analysis of chest X-rays, thereby reducing reading times and improving diagnostic accuracy. This efficiency supports healthcare providers in delivering timely and precise patient care, particularly in detecting and managing critical lung conditions.

VUNO Med-DeepBrain is an AI-powered medical device designed to assist in the diagnosis of neurodegenerative diseases by analyzing brain MRI scans. It automates the segmentation and quantification of over 100 brain regions, providing detailed volumetric data, cortical thickness measurements, and white matter hyperintensity assessments. By comparing a patient's brain atrophy data to a normative population, the software generates a comprehensive report with statistical analyses, visual graphs, and diagrams, aiding clinicians in identifying conditions such as Alzheimer's disease and vascular dementia. Key Features and Functionality: - Automated Brain Segmentation: Utilizes deep learning algorithms to divide brain MRI images into more than 100 distinct regions, facilitating precise analysis. - Quantitative Analysis: Provides volumetric measurements, cortical thickness data, and white matter hyperintensity evaluations for each segmented region. - Normative Comparison: Compares individual patient data against age- and gender-matched normative datasets, offering percentile scores to highlight deviations from typical brain structures. - Comprehensive Reporting: Generates customizable reports featuring statistical results, visual graphs, and color-coded overlays to enhance diagnostic interpretation. - Regulatory Approvals: Certified by the U.S. FDA, CE, and MFDS (K-FDA), ensuring compliance with international medical device standards. Primary Value and User Benefits: VUNO Med-DeepBrain streamlines the traditionally manual and time-consuming process of brain MRI analysis, enabling rapid and accurate assessment of neurodegenerative conditions. By providing objective, quantifiable data, it enhances diagnostic precision, supports early detection of diseases like Alzheimer's, and facilitates monitoring of disease progression. This efficiency not only improves patient outcomes through timely intervention but also optimizes clinical workflows, allowing healthcare professionals to allocate more time to patient care.

VUNO Med®-LungCT AI™ is an advanced artificial intelligence solution designed to assist healthcare professionals in the detection and analysis of pulmonary nodules from chest CT scans. By leveraging cutting-edge AI algorithms, it enhances the accuracy and efficiency of lung disease diagnoses, providing critical data on nodule size, volume, and location. Key Features and Functionality: - Nodule Detection and Quantification: Identifies pulmonary nodules within chest CT images, offering precise measurements of their size and volume. - Comprehensive Nodule Information: Provides detailed data on nodule type, location, calcification, and spiculation, facilitating thorough assessments. - Lung-RADS Categorization: Automatically classifies nodules according to the Lung-RADS system, aiding in standardized reporting and management. - Longitudinal Tracking: Enables comparison of serial CT scans by matching baseline and follow-up images, assisting in monitoring nodule growth over time. - Integration with PACS: Seamlessly integrates results into Picture Archiving and Communication Systems (PACS) using GSPS objects, ensuring user convenience and streamlined workflow. Primary Value and User Benefits: VUNO Med®-LungCT AI™ addresses the critical need for early detection of lung diseases, particularly lung cancer, by providing rapid and accurate analysis of chest CT scans. Its high sensitivity and low false-positive rate reduce the likelihood of missed diagnoses, thereby improving patient outcomes. The solution's ability to deliver detailed nodule information and standardized categorization enhances diagnostic confidence and supports effective patient management. By integrating seamlessly into existing medical imaging workflows, it minimizes additional workload for radiologists, allowing for more efficient and accurate assessments.
Vuno is a technology company specializing in artificial intelligence and deep learning solutions for the healthcare sector. The company focuses on developing innovative tools and platforms that enhance medical imaging, diagnostics, and patient care. Vuno's products aim to improve the accuracy and efficiency of healthcare providers by leveraging advanced algorithms and data analysis. Their solutions are designed to assist in various medical fields, including radiology and pathology, ultimately contributing to better clinical outcomes and streamlined workflows.